- CEO
- Woo-Sik Choi
- Full Time Employees
- 183
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Seoul South Korea
- IPO Date
- Aug 17, 2021
- Business
- DEEP NOID Inc. is a South Korea-based artificial intelligence technology company that specializes in the development and commercialization of deep learning-driven medical diagnostic software, clinical AI development platforms, and automated industrial security inspection systems. Founded in 2008 and headquartered in Seoul, South Korea, the company operates primarily across two core business segments: Medical AI and Industrial AI. The company offers a comprehensive portfolio of proprietary software solutions, including M4CXR, a generative artificial intelligence solution that analyzes chest radiographs to automatically draft preliminary medical reading reports; DEEP:NEURO, a deep learning-based diagnostic aid software for the automated detection and localization of cerebral aneurysms on brain magnetic resonance angiography images; DEEP:CHEST, an AI-enabled chest X-ray analysis solution for the detection of multiple pulmonary diseases and abnormal thoracic conditions; DEEP:SPINE, a computer-aided diagnostic tool for spinal disorders; DEEP:PHI, an open, no-code medical AI development platform that allows medical practitioners and researchers without programming backgrounds to design, train, and validate customized AI models; DEEP:PACS, an AI-integrated Picture Archiving and Communication System designed for medical imaging storage, transmission, and diagnostic workflow integration; DEEP:STORE, a digital marketplace for deploying and sharing verified clinical AI algorithms; DEEP:SECURITY, also offered as SkyMARU:SECURITY, an AI-powered automated X-ray screening system that detects hazardous materials and contraband for aviation, customs, and public security checkpoints; and DEEP:FACTORY, an industrial machine vision solution providing automated defect inspection and quality assurance for smart manufacturing facilities. The company serves university hospitals, tertiary medical centers, research institutions, government agencies, international airports, and industrial manufacturers, with operational reach centered in South Korea and expanding into broader Asia-Pacific, European, and North American markets. In recent operational developments, DEEP NOID obtained medical device approval from South Korea's Ministry of Food and Drug Safety for its generative AI solution M4CXR and entered into multi-hospital software supply agreements with major tertiary institutions, including Jeonbuk National University Hospital and Hwasun Chonnam National University Hospital, while initiating the regulatory pathway toward national health insurance reimbursement coverage. This follows the provisional national health insurance coverage listing for its DEEP:NEURO and DEEP:CHEST systems in South Korea. In its security division, DEEP NOID established a strategic testing and integration agreement with global security technology provider Smiths Detection to incorporate its proprietary threat-detection AI software into dual-view X-ray security inspection equipment. Additionally, the company is transitioning its commercialization framework toward hospital software subscription models and per-case diagnostic billing, while broadening its generative AI research and development roadmap to encompass CT and MRI modalities integrated with hospital Electronic Medical Records and clinical communications systems.